Outcomes of patients with refractory upper GI cancers enrolled in phase I trials: a 10-year analysis from the Sarah Cannon Research Institute UK Drug Development Unit.

ABSTRACT:

Background

Patients with unresectable upper gastrointestinal (UGI) cancers have limited treatment options and poor prognosis. Although phase I trials provide access to novel therapies, their benefits in this population are unclear.

Objectives

We aimed to assess efficacy and survival outcomes of patients with refractory UGI cancers within phase I trials.

Design

We conducted a retrospective pooled analysis of phase I trials enrolling patients with advanced UGI cancers who received at least one dose of the study drug at SCRI UK between 2011 and 2023.

Methods

Efficacy and survival outcomes, including objective response rate (ORR), clinical benefit rate (CBR), disease control rate (DCR), duration of response, progression-free survival (PFS) and overall survival (OS)

SUBMITTER: Antonella C 

PROVIDER: S-EPMC11837055 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature